Medical Bulletin 29/September/2023
Here are the top medical news of the day:
FDA approves Bosutinib for pediatric Chronic Myelogenous Leukemia patients
On September 26, 2023, the Food and Drug Administration (FDA) granted approval for the use of bosutinib in pediatric patients aged 1 year and older who have chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). This approval covers cases that are newly diagnosed or those that are resistant or intolerant to prior therapy. Additionally, the FDA approved a new capsule dosage form, available in 50 mg and 100 mg strengths.
Ginger supplements show promise in reducing autoimmune conditions
A recent study has revealed promising results for the use of ginger extract in controlling neutrophil hyperactivity in autoimmune diseases such as antiphospholipid syndrome (APS) and lupus, as well as in promoting neutrophil health in healthy individuals. Neutrophils are white blood cells involved in the body's immune response.
Ginger, known for its potential health benefits, contains a phytochemical called 6-gingerol, which was previously found to inhibit phosphodiesterase and counteract neutrophil hyperactivity in animal models of APS and lupus.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.